Chemistry:Engasertib

From HandWiki

Engasertib is an investigational new drug that is being evaluated by Vaderis Therapeutics for the treatment of hereditary haemorrhagic telangiectasia. It acts as a c-akt protein inhibitor.[1][2][3][4]

References

  1. ↑ "Engasertib - Vaderis Therapeutics". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800058703. 
  2. ↑ "Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia". The New England Journal of Medicine 393 (21): 2131–2141. November 2025. doi:10.1056/NEJMoa2504411. PMID 41297007. 
  3. ↑ "Engasertib in Hereditary Hemorrhagic Telangiectasia. Reply". The New England Journal of Medicine 394 (8): 825–826. February 2026. doi:10.1056/NEJMc2518633. PMID 41707157. 
  4. ↑ "Engasertib in Hereditary Hemorrhagic Telangiectasia". The New England Journal of Medicine 394 (8): 825. February 2026. doi:10.1056/NEJMc2518633. PMID 41707156. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Engasertib&oldid=4582481"